VYNE Declares Special Cash Dividend Ahead of Yarrow Bioscience Merger
VYNE has more than doubled off its 52-week low of $0.281 on light trading volume (0.2× avg).
Summary
VYNE Therapeutics declared a special cash dividend of $16.5 million, or $0.38 per share, for existing shareholders as part of its proposed reverse merger with Yarrow Bioscience. The dividend is a key step in the merger process, returning value to current holders before the transaction closes. This follows the 10-Q filed in May that first mentioned a large special dividend, but today's declaration makes it official. The move signals confidence in the deal's completion and provides a tangible benefit to shareholders. The merger, which includes a $100 million pre-closing financing, will transform VYNE into a clinical-stage biotech focused on Yarrow's lead asset YB-101.
At the time of this announcement, VYNE was trading at $0.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.4M. The 52-week trading range was $0.28 to $1.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.